Illumina board agrees to spin off Grail rather than sell the cancer diagnostics firm
Illumina’s board has decided to spin out Grail into its own company this month, the DNA sequencing company announced Monday. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
